Inactive Instrument

SourcingLink.net, Inc. Share Price OTC Bulletin Board

US8361714053

Valuation: SourcingLink.net, Inc.

Market Cap	27.06L 23.53L 21.9L 20.11L 37.97L 26Cr 38.56L 2.58Cr 1.01Cr 13Cr 1.02Cr 99.41L 43Cr	P/E 2003 *	-	P/E 2004	-
Enterprise Value	27.06L 23.53L 21.9L 20.11L 37.97L 26Cr 38.56L 2.58Cr 1.01Cr 13Cr 1.02Cr 99.41L 43Cr	EV / Sales 2003	-	EV / Sales 2004	-
Free-Float	100%	Yield 2003 *	-	Yield 2004	-

* Estimated data More valuation ratios

Latest news : SourcingLink.net, Inc.

02/24/02	Krystal Biotech, Inc. : Will it go even higher?
31/21/31	NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc.	CI
10/21/10	Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	CI
04/21/04	Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling Studies	CI
26/21/26	Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent	CI
22/21/22	Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary Oncology	CI
16/21/16	Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory Board	CI
09/21/09	Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials Platform	CI
29/21/29	Oncology Pharma Announces the Appointment of James Smith as New Chief Financial Officer	CI
11/20/11	Oncology Pharma Inc. cancelled the acquisition of acquire 50% stake in Diagnomics, Inc.	CI
06/20/06	Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating Covid-19	CI
20/19/20	Oncology Pharma Inc. announced that it expects to receive $38.4 million in funding from SCP Partners	CI
11/19/11	Oncology Pharma Inc. signed a Letter of Intent to acquire 50% stake in Diagnomics, Inc.	CI

More news

Press Releases: SourcingLink.net, Inc.

12/22/12	Oncology Pharma : Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	PU
29/22/29	Oncology Pharma : Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	PU
06/22/06	Oncology Pharma : Financial Statements (Unaudited) for the year ended March 31, 2022	PU
15/22/15	Oncology Pharma : Financial Statements for the period ended December 31, 2021	PU
15/22/15	Oncology Pharma : Disclosure Statement for the period ended December 31, 2021	PU

More press releases

News in other languages: SourcingLink.net, Inc.

07/24/07

Krystal Biotech, Inc. : ¿Subirá aún más?

More news

Managers and Directors: SourcingLink.net, Inc.

Manager	Title	Age	Since
George Malesek CEO	Chief Executive Officer	-	-

More insiders

Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Companyâ€™s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Companyâ€™s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.

Employees

Sector

Pharmaceuticals

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SOURCINGLINK.NET, INC.	-.--%	+9.50%	-	-	27.06L
ELI LILLY AND COMPANY	-0.53%	-3.95%	+50.70%	+153.56%	1,02400Cr
JOHNSON & JOHNSON	+0.21%	-2.68%	+53.20%	+51.79%	62TCr
ABBVIE INC.	-2.51%	-3.25%	+28.54%	+68.94%	44TCr
ROCHE HOLDING AG	+0.06%	-0.42%	+37.53%	+30.67%	35TCr
ASTRAZENECA PLC	-0.69%	-0.30%	+13.76%	+12.83%	26TCr
NOVO NORDISK A/S	-7.37%	-4.40%	-0.74%	-44.28%	21TCr
AMGEN INC.	-0.64%	+2.43%	+29.74%	+65.93%	21TCr
GILEAD SCIENCES, INC.	-0.82%	+0.70%	+15.05%	+72.05%	16TCr
PFIZER INC.	+0.40%	+1.92%	+6.47%	-29.77%	14TCr
Average	-1.19%	-1.21%	+26.03%	+42.41%	37.99TCr
Weighted average by Cap.	-1.00%	-2.02%	+36.14%	+71.90%

	2003	2004
Net sales	32.8L 28.51L 26.54L 24.37L 46.01L 31Cr 46.73L 3.13Cr 1.23Cr 16Cr 1.23Cr 1.2Cr 52Cr	11.81L 10.27L 10L 9L 16.57L 11Cr 16.82L 1.13Cr 44.21L 5.61Cr 44.35L 43.38L 19Cr
Net income	-15.2L -13.21L -12.3L -11.29L -21.32L -15Cr -21.65L -1.45Cr -56.9L -7.22Cr -57.09L -55.83L -24Cr	-15.65L -13.6L -12.66L -11.63L -21.95L -15Cr -22.29L -1.49Cr -58.58L -7.44Cr -58.78L -57.48L -25Cr
Net Debt	-13.46L -11.7L -10.89L -10L -18.88L -13Cr -19.18L -1.28Cr -50.38L -6.4Cr -50.55L -49.44L -21Cr	17T 14.78T 13.76T 12.63T 23.85T 16.23L 24.22T 2L 63.63T 8L 63.85T 62.44T 27.09L

SourcingLink.net, Inc. Share Price OTC Bulletin Board

Stocks